

1/63




Figure 1

2/63




Figure 2A




Figure 2B

4/63




Figure 3

5/63




Figure 4




Figure 5

7/63




Figure 6

8/63





Figure 7





## Figure 8A

10/63




Figure 8B

11/63







Figure 8C

12/63



Figure 8D

13/63

**14:0 LPG****18:0 LPG****18:1 LPG****Figure 9**

14/63




Figure 10

15/63




Figure 11

16/63




Figure 12



17/63




Figure 13

18/63




Figure 14

19/63




Figure 15

20/63




Figure 16

21/63

## Concentration-dependent inhibition




Figure 17

22/63

## Curve-shift




Figure 18

23/63




Figure 19

24/63




Figure 20



25/63




Figure 21

26/63





Figure 22

27/63


**Control (serum-free)**



**Figure 23**

28/63

**18:0 LPG 10 $\mu$ M**



**Figure 24**

29/63

18:0 LPG 30 $\mu$ M





Figure 25

30/63


**14:0 LPA 10 $\mu$ M**



**Figure 26**

31/63


**14:0 LPA 10 $\mu$ M + 18:0 LPG 10 $\mu$ M**



**Figure 27**

32/63

**14:0 LPA 10 $\mu$ M + 18:0 LPG 30 $\mu$ M**



**Figure 28**



33/63


**Control**



**Figure 29**

34/63


**10 $\mu$ M 18:0 LPG**



**Figure 30**

35/63


**30  $\mu$ M 18:0 LPG**



**Figure 31**

36/63


**Control**



**Figure 32**

37/63


**10 $\mu$ M 18:0 LPG**



**Figure 33**

38/63

**30 $\mu$ M 18:0 LPG**



**Figure 34**

39/63




Figure 35

40/63





Figure 36



41/63


**Control (Serum-free)**



**Figure 37**

42/63


**14:0 LPG (30 $\mu$ M) : LPA1 antagonist**



**Figure 38**

43/63


**18:0 LPG (30 $\mu$ M) : LPA1/2 antagonist**



**Figure 39**

44/63


**18:1 LPG (30 $\mu$ M) : LPA1/2/3 antagonist**



**Figure 40**

45/63


**Control (18:1 LPA 10 $\mu$ M)**



**Figure 41**

46/63


**18:1 LPA  $10\mu\text{M}$  + 14:0 LPG ( $30\mu\text{M}$ )**



**Figure 42**

47/63

**18:1 LPA  $10\mu\text{M}$  + 18:0 LPG ( $30\mu\text{M}$ )**



**Figure 43**

48/63

18:1 LPA  $10\mu\text{M}$  + 18:1 LPG ( $30\mu\text{M}$ )





Figure 44



49/63

**Figure 45**

50/63




Figure 46

51/63




Figure 47

52/63

	Inhibition (%)	
	Without LPA	With LPA
14:0 LPG (30 $\mu$ M)	8%	26% ↑
18:0 LPG (30 $\mu$ M)	41%	37%
18:1 LPG (30 $\mu$ M)	29%	39% ↑

Figure 48

53/63




Figure 49

54/63

	Inhibition (%)	
	Without LPA	With LPA
14:0 LPG (30 $\mu$ M)	4%	16% ↑
18:0 LPG (30 $\mu$ M)	46%	49%
18:1 LPG (30 $\mu$ M)	13%	32% ↑

Figure 50

55/63



**Figure 51**

56/63




Figure 52



57/63




Figure 53

58/63





Figure 54

59/63

**Figure 55**

60/63







Figure 56

61/63

**Figure 57**

**Figure 58**

**Figure 59**